| Dr David J Hunt, MD | |
|
331 Laidley St, Ste 301, Charleston, WV 25301-1605 | |
| (304) 346-4400 | |
| (304) 346-0704 |
| Full Name | Dr David J Hunt |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 29 Years |
| Location | 331 Laidley St, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740284579 | NPI | - | NPPES |
| 64018005 | Medicaid | KY | |
| 1802229000 | Medicaid | WV | |
| 2197831 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 20265 (West Virginia) | Secondary |
| 207WX0107X | Ophthalmology - Retina Specialist | 20265 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital | Charleston, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Retina Consultants Pllc | 3375636178 | 6 |
News Archive
Corneal transplantation has been performed with increasing success for more than 100 years. In the last 20 years, standards, outcomes and developments in the field of corneal transplantation and eye banking have been discussed at the annual meetings of the European Eye Bank Association (EEBA) to share and promote good practice and guarantee a high level of safety for the recipients.
Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.
Faith-based organisations are crucial in achieving the promise of universal health coverage—an adequate standard of health care for all people—especially for poor and marginalised groups, according to a new three-part Series on faith-based health care, published in The Lancet.
Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.
› Verified 9 days ago
| Entity Name | Retina Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902800758 PECOS PAC ID: 3375636178 Enrollment ID: O20070911000089 |
News Archive
Corneal transplantation has been performed with increasing success for more than 100 years. In the last 20 years, standards, outcomes and developments in the field of corneal transplantation and eye banking have been discussed at the annual meetings of the European Eye Bank Association (EEBA) to share and promote good practice and guarantee a high level of safety for the recipients.
Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.
Faith-based organisations are crucial in achieving the promise of universal health coverage—an adequate standard of health care for all people—especially for poor and marginalised groups, according to a new three-part Series on faith-based health care, published in The Lancet.
Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David J Hunt, MD Po Box 3970, Charleston, WV 25339-3970 Ph: (304) 346-4400 | Dr David J Hunt, MD 331 Laidley St, Ste 301, Charleston, WV 25301-1605 Ph: (304) 346-4400 |
News Archive
Corneal transplantation has been performed with increasing success for more than 100 years. In the last 20 years, standards, outcomes and developments in the field of corneal transplantation and eye banking have been discussed at the annual meetings of the European Eye Bank Association (EEBA) to share and promote good practice and guarantee a high level of safety for the recipients.
Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.
Faith-based organisations are crucial in achieving the promise of universal health coverage—an adequate standard of health care for all people—especially for poor and marginalised groups, according to a new three-part Series on faith-based health care, published in The Lancet.
Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.
› Verified 9 days ago
Dr. Paul Frederick Francke, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E Ste 203, Charleston, WV 25301 Phone: 304-343-4124 Fax: 304-343-4167 | |
Dr. Huseyin Kadikoy, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E, Charleston, WV 25301 Phone: 304-388-6630 Fax: 304-388-6629 | |
Dr. Stephen Paul Cassis, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 301 49th St Se, Suite A, Charleston, WV 25304 Phone: 304-925-3937 Fax: 304-925-4336 | |
Dr. Audrey Lilian Hunt, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E, Charleston, WV 25301 Phone: 304-388-6630 Fax: 304-388-6629 | |
Richard Mark Hatfield, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 331 Laidley St, Ste 301, Charleston, WV 25301 Phone: 304-346-4400 Fax: 304-346-0704 | |
James White Caudill, MD RETIRED Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 501 Summers St, Charleston, WV 25301 Phone: 304-343-3937 Fax: 304-344-3957 | |
Dr. Sara E O'connor, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1306 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-343-4371 Fax: 304-353-0215 |